Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)

Q32 Bio's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $354000.0 for Q1 2023.

• In Q1 2023, Current Deferred Revenue fell 88.97% year-over-year to $354000.0; the TTM figure through Mar 2023 stood at $354000.0 (down 88.97% YoY), while the FY2022 annual figure was $1.2 million, down 63.97% from the prior year.
• Current Deferred Revenue was $354000.0 for Q1 2023 at Q32 Bio, down from $1.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $5.6 million in Q4 2020 to a low of $354000.0 in Q1 2023.
• Historically, Current Deferred Revenue has averaged $2.1 million across 5 years, with a median of $1.3 million in 2019.
• The sharpest annual moves came in 2021 and 2023: Current Deferred Revenue soared 569.77% in 2021, then tumbled 88.97% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $1.3 million in 2019, then surged by 328.94% to $5.6 million in 2020, then tumbled by 43.04% to $3.2 million in 2021, then plunged by 63.97% to $1.2 million in 2022, then sank by 69.38% to $354000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $354000.0 (Q1 2023), $1.2 million (Q4 2022), and $2.0 million (Q3 2022), per Business Quant data.